Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy

Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy

•SBRT dose levels of 40 Gy associated with improved post-treatment biopsy outcomes.•Two-year positive post-treatment biopsies pre-dated PSA failure in majority of patients.•PSA level at time of 2-year biopsy was 40 Gy, respectively. In a multivariable model, patients treated with SBRT doses of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Radiotherapy and oncology 2021-06, Vol.159, p.33-38
Hauptverfasser: Zelefsky, Michael J., Goldman, Debra A., Hopkins, Margaret, Pinitpatcharalert, Attapol, McBride, Sean, Gorovets, Daniel, Ehdaie, Behfar, Fine, Samson W., Reuter, Victor E., Tyagi, Neelam, Happersett, Laura, Teyateeti, Achiraya, Zhang, Zhigang, Kollmeier, Marisa A.
Format: Artikel
Sprache:eng
Schlagworte:
Biopsy
Humans
Life Sciences & Biomedicine
Localized prostate cancer
Male
Oncology
Post-treatment biopsy
Predictive factors
Prostate-Specific Antigen
Prostatic Neoplasms - radiotherapy
Prostatic Neoplasms - surgery
Radiology, Nuclear Medicine & Medical Imaging
Radiosurgery - adverse effects
Science & Technology
Stereotactic body radiotherapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•SBRT dose levels of 40 Gy associated with improved post-treatment biopsy outcomes.•Two-year positive post-treatment biopsies pre-dated PSA failure in majority of patients.•PSA level at time of 2-year biopsy was 40 Gy, respectively. In a multivariable model, patients treated with SBRT doses of
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2021.02.008